ME

MEDINET Co., Ltd.

A CDMO for cell therapy and regenerative medicine development & manufacturing.

2370 | T

Overview

Corporate Details

ISIN(s):
JP3920990003
LEI:
Country:
Japan
Address:
品川区勝島一丁目5番21号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

MEDINET Co., Ltd. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the regenerative medicine and cell therapy sectors. Since its establishment in 1999, the company has provided comprehensive, one-stop solutions across the entire value chain, from pre-clinical research and technology transfer to manufacturing and commercial launch. Key services include process development, quality control, quality assurance, and logistics. MEDINET operates an advanced cell processing facility compliant with Japanese, US, and European GCTP standards, leveraging its extensive experience and deep expertise in Japan's regulatory framework to support its clients' development and manufacturing needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-03 08:09
Registration Form
有価証券届出書(参照方式)
Japanese 173.2 KB
2025-05-14 08:33
Report Publication Announcement
確認書
Japanese 8.3 KB
2025-05-14 08:32
Interim / Quarterly Report
半期報告書-第30期(2024/10/01-2025/09/30)
Japanese 204.7 KB
2024-12-26 04:04
AGM Information
臨時報告書
Japanese 25.2 KB
2024-12-18 07:40
Registration Form
確認書
Japanese 8.3 KB
2024-12-18 07:38
Governance Information
内部統制報告書-第29期(2023/10/01-2024/09/30)
Japanese 21.6 KB
2024-12-18 07:35
Annual Report
有価証券報告書-第29期(2023/10/01-2024/09/30)
Japanese 1.3 MB
2024-05-14 08:02
Report Publication Announcement
確認書
Japanese 8.3 KB
2024-05-14 08:00
Quarterly Report
四半期報告書-第29期第2四半期(2024/01/01-2024/03/31)
Japanese 200.2 KB
2024-02-13 07:04
Report Publication Announcement
確認書
Japanese 8.3 KB
2024-02-13 07:01
Quarterly Report
四半期報告書-第29期第1四半期(2023/10/01-2023/12/31)
Japanese 152.4 KB
2023-12-21 07:03
Registration Form
確認書
Japanese 8.3 KB
2023-12-21 07:02
Governance Information
内部統制報告書-第28期(2022/10/01-2023/09/30)
Japanese 21.7 KB
2023-12-21 07:01
Annual Report
有価証券報告書-第28期(2022/10/01-2023/09/30)
Japanese 1.3 MB
2023-08-10 08:02
Report Publication Announcement
確認書
Japanese 8.3 KB

Automate Your Workflow. Get a real-time feed of all MEDINET Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MEDINET Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MEDINET Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
Trevi Therapeutics, Inc. Logo
Clinical-stage biopharma developing an oral therapy for chronic cough in IPF and RCC.
United States of America
TRVI
TRINITY BIOTECH PLC Logo
Develops and markets clinical diagnostic test kits and biosensors for labs and point-of-care.
United States of America
TRIB
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD
UCB Logo
UCB
Biopharma firm developing treatments for severe neurological and immunological diseases.
Belgium
UCB
Ultragenyx Pharmaceutical Inc. Logo
Develops and commercializes novel therapies for rare and ultra-rare genetic diseases.
United States of America
RARE
Develops biopharma therapies for endocrinology, ophthalmology, and dermatology needs.
Hong Kong
690
Unicycive Therapeutics, Inc. Logo
A clinical-stage biotech developing novel treatments for kidney diseases, led by oxylanthanum carbonate.
United States of America
UNCY

Talk to a Data Expert

Have a question? We'll get back to you promptly.